Insider Transactions in Q2 2021 at Talaris Therapeutics, Inc. (TALS)

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
May 11 2021	Clarus Lifesciences Iii, L.P. > 10% Shareholder	BUY Open market or private purchase	Indirect	30,000 +0.42%	$510,000 $17.0 P/Share
May 11 2021	Clarus Lifesciences Iii, L.P. > 10% Shareholder	BUY Conversion of derivative security	Indirect	8,059,315 +33.25%	-
May 11 2021	Clarus Defined Exit I, L.P. > 10% Shareholder	BUY Open market or private purchase	Indirect	30,000 +0.42%	$510,000 $17.0 P/Share
May 11 2021	Clarus Defined Exit I, L.P. > 10% Shareholder	BUY Conversion of derivative security	Indirect	8,059,315 +33.25%	-
May 11 2021	Longitude Capital Partners Iii, LLC > 10% Shareholder	BUY Open market or private purchase	Indirect	235,000 +6.8%	$3,995,000 $17.0 P/Share
May 11 2021	Longitude Capital Partners Iii, LLC > 10% Shareholder	BUY Conversion of derivative security	Indirect	2,985,775 +50.0%	-
May 11 2021	Sandip Agarwala Director	BUY Open market or private purchase	Indirect	235,000 +6.8%	$3,995,000 $17.0 P/Share
May 11 2021	Sandip Agarwala Director	BUY Conversion of derivative security	Indirect	2,985,775 +50.0%	-

Receive a notification when an Institution or Guru buys or sells TALS shares.

Notify only if

Value

Get notified when an Talaris Therapeutics, Inc. insider buys or sells TALS shares.

Notify only if

Operation

Value

Type

Receive news related to Talaris Therapeutics, Inc.